Involvement of the prostaglandin D2 signal pathway in retinoid-inducible gene 1 (RIG1)-mediated suppression of cell invasion in testis cancer cells

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1823, Issue 12, 2012, Pages 2227-2236

  Wu, Chang Chieh ^a   Shyu, Rong Yaun ^b   Wang, Chun Hua ^b   Tsai, Tzung Chieh ^c   Wang, Lu Kai ^d   Chen, Mao Liang ^b   Jiang, Shun Yuan ^b   Tsai, Fu Ming ^b  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^c NATIONAL CHIAYI UNIVERSITY   (Taiwan)

^d NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

HREV107 type II tumor suppressor; Prostaglandin D2 synthase; Retinoid inducible gene 1; Testis

Indexed keywords

CYCLIC AMP; PROSTAGLANDIN D2; PROSTAGLANDIN D2 SYNTHASE; PROSTAGLANDIN SYNTHASE; RETINOIC ACID INDUCIBLE PROTEIN I; TRANSCRIPTION FACTOR SOX9; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER TISSUE; CELL DEATH; CELL INVASION; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SERTOLI CELL; SIGNAL TRANSDUCTION; SRY GENE; TESTIS CANCER; TISSUE DIFFERENTIATION; TWO HYBRID SYSTEM;

APOPTOSIS; BLOTTING, WESTERN; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CYCLIC AMP; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOPRECIPITATION; INTRAMOLECULAR OXIDOREDUCTASES; LIPOCALINS; MALE; NEOPLASM INVASIVENESS; PROSTAGLANDIN D2; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, PROSTAGLANDIN; RECEPTORS, RETINOIC ACID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TESTICULAR NEOPLASMS; TESTIS; TUMOR CELLS, CULTURED;

EID: 84867414311     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2012.08.013     Document Type: Article

References (44)

1. Huang S.L., Shyu R.Y., Yeh M.Y., Jiang S.Y. Cloning and characterization of a novel retinoid-inducible gene 1(RIG1) deriving from human gastric cancer cells. Mol. Cell. Endocrinol. 2000, 159:15-24.
2. DiSepio D., Ghosn C., Eckert R.L., Deucher A., Robinson N., Duvic M., Chandraratna R.A., Nagpal S. Identification and characterization of a retinoid-induced class II tumor suppressor/growth regulatory gene. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:14811-14815.
3. Casanova B., de la Fuente M.T., Garcia-Gila M., Sanz L., Silva A., Garcia-Marco J.A., Garcia-Pardo A. The class II tumor-suppressor gene RARRES3 is expressed in B cell lymphocytic leukemias and down-regulated with disease progression. Leukemia 2001, 15:1521-1526.
4. Anantharaman V., Aravind L. Evolutionary history, structural features and biochemical diversity of the NlpC/P60 superfamily of enzymes. Genome Biol. 2003, 4:R11.
5. Hughes P.J., Stanway G. The 2A proteins of three diverse picornaviruses are related to each other and to the H-rev107 family of proteins involved in the control of cell proliferation. J. Gen. Virol. 2000, 81:201-207.
6. Hajnal A., Klemenz R., Schafer R. Subtraction cloning of H-rev107, a gene specifically expressed in H-ras resistant fibroblasts. Oncogene 1994, 9:479-490.
7. Husmann K., Sers C., Fietze E., Mincheva A., Lichter P., Schafer R. Transcriptional and translational downregulation of H-REV107, a class II tumour suppressor gene located on human chromosome 11q11-12. Oncogene 1998, 17:1305-1312.
8. Akiyama H., Hiraki Y., Noda M., Shigeno C., Ito H., Nakamura T. Molecular cloning and biological activity of a novel Ha-Ras suppressor gene predominantly expressed in skeletal muscle, heart, brain, and bone marrow by differential display using clonal mouse EC cells, ATDC5. J. Biol. Chem. 1999, 274:32192-32197.
9. Ito H., Akiyama H., Shigeno C., Nakamura T. Isolation, characterization, and chromosome mapping of a human A-C1 Ha-Ras suppressor gene (HRASLS). Cytogenet. Cell Genet. 2001, 93:36-39.
10. Tsai F.M., Shyu R.Y., Jiang S.Y. RIG1 inhibits the Ras/mitogen-activated protein kinase pathway by suppressing the activation of Ras. Cell. Signal. 2006, 18:349-358.
11. Tsai F.M., Shyu R.Y., Jiang S.Y. RIG1 suppresses Ras activation and induces cellular apoptosis at the Golgi apparatus. Cell. Signal. 2007, 19:989-999.
12. Sturniolo M.T., Chandraratna R.A., Eckert R.L. A novel transglutaminase activator forms a complex with type 1 transglutaminase. Oncogene 2005, 24:2963-2972.
13. Sturniolo M.T., Dashti S.R., Deucher A., Rorke E.A., Broome A.M., Chandraratna R.A., Keepers T., Eckert R.L. A novel tumor suppressor protein promotes keratinocyte terminal differentiation via activation of type I transglutaminase. J. Biol. Chem. 2003, 278:48066-48073.
14. Duvic M., Helekar B., Schulz C., Cho M., DiSepio D., Hager C., DiMao D., Hazarika P., Jackson B., Breuer-McHam J., Young J., Clayman G., Lippman S.M., Chandraratna R.A., Robinson N.A., Deucher A., Eckert R.L., Nagpal S. Expression of a retinoid-inducible tumor suppressor, tazarotene-inducible gene-3, is decreased in psoriasis and skin cancer. Clin. Cancer Res. 2000, 3249-3259.
15. Siegrist S., Feral C., Chami M., Solhonne B., Mattei M.G., Rajpert-De Meyts E., Guellaen G., Bulle F. hH-Rev107, a class II tumor suppressor gene, is expressed by post-meiotic testicular germ cells and CIS cells but not by human testicular germ cell tumors. Oncogene 2001, 20:5155-5163.
16. Shyu R.Y., Jiang S.Y., Chou J.M., Shih Y.L., Lee M.S., Yu J.C., Chao P.C., Hsu Y.J., Jao S.W. RARRES3 expression positively correlated to tumour differentiation in tissues of colorectal adenocarcinoma. Br. J. Cancer 2003, 89:146-151.
17. Lotz K., Kellner T., Heitmann M., Nazarenko I., Noske A., Malek A., Gontarewicz A., Schafer R., Sers C. Suppression of the TIG3 tumor suppressor gene in human ovarian carcinomas is mediated via mitogen-activated kinase-dependent and -independent mechanisms. Int. J. Cancer 2005, 116:894-902.
18. Sers C., Emmenegger U., Husmann K., Bucher K., Andres A.C., Schafer R. Growth-inhibitory activity and downregulation of the class II tumor-suppressor gene H-rev107 in tumor cell lines and experimental tumors. J. Cell Biol. 1997, 136:935-944.
19. Huang S.L., Shyu R.Y., Yeh M.Y., Jiang S.Y. The retinoid-inducible gene I: effect on apoptosis and mitogen-activated kinase signal pathways. Anticancer Res. 2002, 22:799-804.
20. Duncan R.E., Sarkadi-Nagy E., Jaworski K., Ahmadian M., Sul H.S. Identification and functional characterization of adipose-specific phospholipase A2 (AdPLA). J. Biol. Chem. 2008, 283:25428-25436.
21. Uyama T., Jin X.H., Tsuboi K., Tonai T., Ueda N. Characterization of the human tumor suppressors TIG3 and HRASLS2 as phospholipid-metabolizing enzymes. Biochim. Biophys. Acta 2009, 1791:1114-1124.
22. Smith W.L., DeWitt D.L., Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 2000, 69:145-182.
23. Narumiya S., Sugimoto Y., Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol. Rev. 1999, 79:1193-1226.
24. Adams I.R., McLaren A. Sexually dimorphic development of mouse primordial germ cells: switching from oogenesis to spermatogenesis. Development 2002, 129:1155-1164.
25. Malki S., Nef S., Notarnicola C., Thevenet L., Gasca S., Mejean C., Berta P., Poulat F., Boizet-Bonhoure B. Prostaglandin D2 induces nuclear import of the sex-determining factor SOX9 via its cAMP-PKA phosphorylation. EMBO J. 2005, 24:1798-1809.
26. Tsai F.M., Shyu R.Y., Lin S.C., Wu C.C., Jiang S.Y. Induction of apoptosis by the retinoid inducible growth regulator RIG1 depends on the NC motif in HtTA cervical cancer cells. BMC Cell Biol. 2009, 10:15.
27. Shyu R.Y., Hsieh Y.C., Tsai F.M., Wu C.C., Jiang S.Y. Cloning and functional characterization of the HRASLS2 gene. Amino Acids 2008, 35:129-137.
28. Reddy S.T., Winstead M.V., Tischfield J.A., Herschman H.R. Analysis of the secretory phospholipase A2 that mediates prostaglandin production in mast cells. J. Biol. Chem. 1997, 272:13591-13596.
29. Fujishima H., Sanchez Mejia R.O., Bingham C.O., Lam B.K., Sapirstein A., Bonventre J.V., Austen K.F., Arm J.P. Cytosolic phospholipase A2 is essential for both the immediate and the delayed phases of eicosanoid generation in mouse bone marrow-derived mast cells. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:4803-4807.
30. Moniot B., Declosmenil F., Barrionuevo F., Scherer G., Aritake K., Malki S., Marzi L., Cohen-Solal A., Georg I., Klattig J., Englert C., Kim Y., Capel B., Eguchi N., Urade Y., Boizet-Bonhoure B., Poulat F. The PGD2 pathway, independently of FGF9, amplifies SOX9 activity in Sertoli cells during male sexual differentiation. Development 2009, 136:1813-1821.
31. Baker P.J., O'Shaughnessy P.J. Expression of prostaglandin D synthetase during development in the mouse testis. Reproduction 2001, 122:553-559.
32. Zhang A., Dong Z., Yang T. Prostaglandin D2 inhibits TGF-beta1-induced epithelial-to-mesenchymal transition in MDCK cells. Am. J. Physiol. Renal Physiol. 2006, 291:F1332-F1342.
33. Yoshida T., Ohki S., Kanazawa M., Mizunuma H., Kikuchi Y., Satoh H., Andoh Y., Tsuchiya A., Abe R. Inhibitory effects of prostaglandin D2 against the proliferation of human colon cancer cell lines and hepatic metastasis from colorectal cancer. Surg. Today 1998, 28:740-745.
34. Wang D., Dubois R.N. Eicosanoids and cancer. Nat. Rev. Cancer 2010, 10:181-193.
35. Passeron T., Valencia J.C., Namiki T., Vieira W.D., Passeron H., Miyamura Y., Hearing V.J. Upregulation of SOX9 inhibits the growth of human and mouse melanomas and restores their sensitivity to retinoic acid. J. Clin. Invest. 2009, 119:954-963.
36. Ueno M., Nakashima J., Nakanoma T., Ohigashi T., Hirata R., Iida M., Suzuki M., Sano M., Yamada Y., Deguchi N. Retinoic acid-induced cell growth inhibition and differentiation in testicular carcinoma cells in culture. Hum. Cell 1997, 10:151-158.
37. Miller W.H., Moy D., Li A., Grippo J.F., Dmitrovsky E. Retinoic acid induces down-regulation of several growth factors and proto-oncogenes in a human embryonal cancer cell line. Oncogene 1990, 5:511-517.
38. Ling S., Chang X., Schultz L., Lee T.K., Chaux A., Marchionni L., Netto G.J., Sidransky D., Berman D.M. An EGFR-ERK-SOX9 signaling cascade links urothelial development and regeneration to cancer. Cancer Res. 2011, 71:3812-3821.
39. Zhao L., Li G., Zhou G.Q. SOX9 directly binds CREB as a novel synergism with the PKA pathway in BMP-2-induced osteochondrogenic differentiation. J. Bone Miner. Res. 2009, 24:826-836.
40. Kobayashi A., Chang H., Chaboissier M.C., Schedl A., Behringer R.R. Sox9 in testis determination. Ann. N. Y. Acad. Sci. 2005, 1061:9-17.
41. Wilhelm D., Hiramatsu R., Mizusaki H., Widjaja L., Combes A.N., Kanai Y., Koopman P. SOX9 regulates prostaglandin D synthase gene transcription in vivo to ensure testis development. J. Biol. Chem. 2007, 282:10553-10560.
42. Gerena R.L., Eguchi N., Urade Y., Killian G.J. Stage and region-specific localization of lipocalin-type prostaglandin D synthase in the adult murine testis and epididymis. J. Androl. 2000, 21:848-854.
43. Ou C.C., Hsu S.C., Hsieh Y.H., Tsou W.L., Chuang T.C., Liu J.Y., Kao M.C. Downregulation of HER2 by RIG1 involves the PI3K/Akt pathway in ovarian cancer cells. Carcinogenesis 2008, 29:299-306.
44. Deucher A., Nagpal S., Chandraratna R.A., Di Sepio D., Robinson N.A., Dashti S.R., Eckert R.L. The carboxy-terminal hydrophobic domain of TIG3, a class II tumor suppressor protein, is required for appropriate cellular localization and optimal biological activity. Int. J. Oncol. 2000, 17:1195-1203.